Cellebrite Enterprise Solutions 2023 Industry Trends Report Finds 70 Percent of eDiscovery Professionals State Accessing Data Offsite Is a Major Endpoint Collection Problem
Hybrid work causing major data collection headaches for eDiscovery professionals, slowing down corporate fraud, IP theft and sexual assault investigations
Collecting data from offsite mobile devices, chat apps and remote employees are some of the top challenges faced by corporate investigators
PETAH TIKVA, Israel and TYSONS CORNER, Va., Jan. 24, 2023 (GLOBE NEWSWIRE) -- A study commissioned by digital intelligence leader Cellebrite DI Ltd. (NASDAQ: CLBT) has revealed that hybrid work is creating major data collection headaches for eDiscovery professionals and corporate investigators and is slowing down corporate fraud, IP theft and sexual harassment investigations.
The data reveals that both in-house and agency investigators are facing new challenges caused by the pandemic-induced rise in hybrid and remote working. The top three issues highlighted by respondents are as follows:
- 70 percent of eDiscovery professionals say accessing data from offsite mobile devices is a major endpoint collection problem
- 63 percent of eDiscovery professional say accessing data from WhatsApp, WeChat and Telegram is a major endpoint collection problem
- 56 percent of eDiscovery professionals say collecting data from employees working remotely is a major endpoint collection problem
The data, gathered from 550 eDiscovery professionals and corporate investigators in 45 countries, also illustrates how the abundance of chat and collaboration tools – again accelerated by the pandemic – is spreading digital evidence across a broadening range of platforms.
Cellebrite Enterprise Solutions’ Endpoint Inspector helps relieve these pain points by:
- Creating and defining targeted collections from remote computers, remote mobile devices, and supported cloud workplace applications like Office365, Google Workspace, Slack and Box
- Easily collecting only what is needed from endpoints and cloud workplace applications without employees having to hand over their device, saving valuable resources
- Accessing a single source for cloud workplace app collection without logging into every app and pulling all data from multiple sources for every employee
Ken Basore, General Manager at Cellebrite Enterprise Solutions comments:“This study clearly shows that the rise in hybrid working is creating new challenges for investigators such as remote data extraction and the splintering of data across emerging collaboration tools. Organizations must equip professionals with the people, skills and technology required to extract, analyze, manage and store remote digital evidence. If these investments aren’t made, there will be real world consequences including rising cases of business fraud, growing, exposure to civil litigation, possible adverse judgments, unrecoverable financial losses and victims of workplace crimes that do not get the justice they need.”
Joe Pochron, Digital Forensics & Insider Threat Lead, Forensic & Integrity Services Ernst & Young LLP: “As you can see from Cellebrite’s Industry Trends survey, remote collection is growing more and more important for eDiscovery professionals. The growing landscape of collaboration tools provides a deluge of information to investigate. Thankfully, Cellebrite Enterprise Solutions provides the tools necessary to zone in on the data needed for corporate examinations.”
The report, which can be downloaded here, contains a wealth of data about the different ways corporate investigators and third-party service providers are using digital evidence. It contains actionable recommendations for organizations looking to enhance their remote collection capabilities and management of digital artefacts.
Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com.
About Cellebrite Enterprise Solutions
In a world that’s evolving rapidly, Cellebrite Enterprise Solutions looks beyond the horizon to design solutions to keep data within reach, transform it, and reveal important insights to protect your business and employees. From headquarters to home office, eDiscovery professionals and corporate investigators can access endpoints anywhere with Cellebrite’s enterprise solution offerings.
Public Relations and Corporate Communications Director
+1 404 804 5910
Investor RelationsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease8.2.2023 22:01:00 CET | Press release
The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response at Week 58The safety findings were generally consistent with the known profile of filgotinib in rheumatoid arthritis (RA) and ulcerative colitis (UC)Galapagos decided not to submit a Marketing Authorization Application in Europe based on these topline dataGalapagos remains fully committed to filgotinib, a JAK1 preferential inhibitor orally administered once daily, and its approved indications, RA and UC, and is on track to start a Phase 3 trial in axial spondyloarthritis (AxSpA) later this year Mechelen, Belgium; 8February2023, 22:01CET; regulated information; Galapagos NV (Euronext & NASDAQ: GLPG) todayannouncedthe topline results from DIVERSITY,a global Phase 3 trial to evaluate the safety and efficacy of filgotinib,100mg or 200mg once dail
X8 AG Submits a Swiss Fintech Licence Application8.2.2023 21:21:16 CET | Press release
X8 AG submitted the application for a Swiss FinTech license according to Art. 1b Banking Act with the intention of operating a regulated global stablecoin system BAAR, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The X8 AG team has successfully submitted the application to FINMA, the Swiss Financial Market Supervisory Authority, for the Swiss FinTech license according to Article 1b Banking Act. This marks an important step for X8 AG on its way to become a fully regulated global stablecoin system and significantly differentiating itself from the current non-regulated crypto space. Switzerland offers one of the most advanced regulatory frameworks for digital assets. X8 AG believes that designing its stablecoin system under Swiss law is the best starting point to achieve a global X8 cross-border framework for payments. Full compliance with the Swiss regulatory framework strengthens the high standards of protection for clients. X8 AG aims to empower users and their money with frictionles
GN Store Nord announces intention to initiate a rights issue8.2.2023 20:08:16 CET | Press release
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering memorandum or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017. The offer to acquire securities pursuant to the offering is made, and any investor should make their investment decision, solely on the basis of information that is contained in the prospectus to be made generally available in Denmark in connection with the offering. GN Store Nord announces intention to initiate a rights issue In accordance with our announcement on November 11, 2022, GN has conducted a comprehensive review of the appropriate capital structure. In light of the current macroeconomic environment and GN’s leverage, GN announces today that it intends to raise gross proceeds of DKK 7 billion in the first half
Nokia Corporation: Repurchase of own shares on 08.02.20238.2.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 8 February 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 08.02.2023 Espoo, Finland – On 8 February 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL282,2294.39CEUX20,3804.39AQEU6,3784.39TQEX5,0134.38Total314,0004.39 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023
Interim report 2022/23 - 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter8.2.2023 18:57:07 CET | Press release
ANNOUNCEMENT NO. 234 9 February 2023 Interim report for the first half of 2022/23 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter Steen Søndergaard, CEO: “Following a very satisfactory 2021/22 with historically high revenue and operating profit growth rates, revenue for the first half of 2022/23 unfortunately disappointed, despite 15% growth. Second quarter sales of instruments, particularly in the North American market, were challenged by a generally more subdued investment sentiment in our primary business segment, cell-based therapy. Our order intake was mainly impacted by weakened demand from capital-sensitive development companies. On the other hand, we saw continued satisfactory growth in sales of consumables and services. Despite the unfavourable market conditions, our earnings continued to grow. While our market is currently affected by the prevailing macroeconomic environment, we have a strong underlying